RECEIVED CENTRAL FAX CENTER

JUN 1 6 2005

Facsimile

Lilly

Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U.S.A.

Legal Department - Patent Division

Date: June 16, 2005

To: Examiner J. Jason Galvez

Company: USPTO Fax: 1-571-273-8300 Phone: 571-272-2935

From: Thomas Webster Fax: 317-276-5172 Phone: 317-276-3334

Total Pages: 7

Subject:

Serial No.: Art Unit: 10/089984

1647

BUMOL Thomas Frank

First Applicant: Docket No.:

X-13199

RECEIVED OIPE/IAP

JUN 1 7 2005

PRIVILEGED AND CONFIDENTIAL COMMUNICATION

Message:

Examiner Galvez,

Please see attached Reply and Amendment. These documents were previously faxed to the old fax number. If I need to do anything further to ensure they are not filed twice, please let me know. Thank you for getting back with me so promptly today.

If there are any transmittal problems please call Kim Landers at (317) 277-1469.

This facsimile message is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If you have received this facsimile in error, please notify us immediately by telephone (collect), and return the original message to us at the above address via U.S. Postal Service.

Answers That Matter.

CERTIFICATION OF FACSIMILE TRANSMISSION	
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.	i
Kim Landers	
Type or print name of person signing certification	
Kim Landers June 16, 2005	

First Applicant:

BUMOL Thomas Frank

Group Art Unit: 1647

Serial No.:

10/089984

GALVEZ, JAMES JASON

Application Date: October 6, 2000

Conf No.: 3218

US Nat'l Entry

Date (if applicable): July 1, 2002

For:

THERAPEUTIC APPLICATIONS OF FLINT POLYPEPTIDES

Docket No.:

X13199 .

REPLY UNDER 37 C.F.R. 1.111 & AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Introductory Comments

In response to the Office Action dated January 18, 2005, please amend this application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 3 of this paper.

06/17/2005 SFELEKE1 00000077 050840 10089984

01 FC:1252

450.00 DA